Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Ronald P. Taylor; Margaret A. Lindorfer; John P. Atkinson

doi:10.1002/trc2.12067

Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Ronald P. Taylor, Margaret A. Lindorfer, John P. Atkinson

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti-amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.

Original language	English
Article number	e12067
Journal	Alzheimer's and Dementia: Translational Research and Clinical Interventions
Volume	6
Issue number	1
DOIs	https://doi.org/10.1002/trc2.12067
State	Published - 2020

Keywords

Alzheimer's disease
amyloid beta
bispecific monoclonal antibodies
complement receptor 1
erythrocyte
human

Access to Document

10.1002/trc2.12067

Cite this

@article{92ee1b5d57f34d10a680a484b715116d,

title = "Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes",

abstract = "We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti-amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.",

keywords = "Alzheimer's disease, amyloid beta, bispecific monoclonal antibodies, complement receptor 1, erythrocyte, human",

author = "Taylor, \{Ronald P.\} and Lindorfer, \{Margaret A.\} and Atkinson, \{John P.\}",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Alzheimer's \& Dementia: Translational Research \& Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association",

year = "2020",

doi = "10.1002/trc2.12067",

language = "English",

volume = "6",

journal = "Alzheimer's and Dementia: Translational Research and Clinical Interventions",

issn = "2352-8737",

number = "1",

}

TY - JOUR

T1 - Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

AU - Taylor, Ronald P.

AU - Lindorfer, Margaret A.

AU - Atkinson, John P.

PY - 2020

Y1 - 2020

N2 - We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti-amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.

AB - We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti-amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.

KW - Alzheimer's disease

KW - amyloid beta

KW - bispecific monoclonal antibodies

KW - complement receptor 1

KW - erythrocyte

KW - human

UR - https://www.scopus.com/pages/publications/85095950299

U2 - 10.1002/trc2.12067

DO - 10.1002/trc2.12067

M3 - Article

C2 - 32885023

AN - SCOPUS:85095950299

SN - 2352-8737

VL - 6

JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions

JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions

IS - 1

M1 - e12067

ER -

Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this